GlassScriptPhysician profile
Anil K Singh
NPI 1023214897
$3,485.50
in general payments reported to CMS, 2019-2025
28 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $178 · 2021: $417 · 2022: $607 · 2023: $610 · 2024: $780 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,971 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,971.24 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $867.81 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Vifor Pharma, INC. | $551.53 | 2020-2025 | Veltassa |
| Amgen INC. | $348.66 | 2021-2025 | Repatha, Repatha, Otezla |
| Genzyme Corporation | $294.29 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $222.17 | 2021-2025 | |
| Glaxosmithkline, LLC. | $205.24 | 2019-2025 | Trelegy Ellipta, Benlysta |
| Lilly USA, LLC | $136.67 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $129.30 | 2019-2024 | Wegovy |
| Pfizer INC. | $122.84 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $75.99 | 2023-2024 | Tarpeyo |
| Abbott Laboratories | $74.41 | 2021-2024 | Freestyle Libre 3 |
| Shield Therapeutics INC | $64.76 | 2022-2025 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $57.11 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.41 | 2022 | |
| Opko Pharmaceuticals, LLC | $40.83 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amphastar Pharmaceuticals, INC. | $31.57 | 2025 | |
| Sanofi-Aventis U.S. LLC | $30.10 | 2024 | |
| Aerin Medical INC. | $28.57 | 2023 | |
| Dexcom, INC. | $23.42 | 2022 | |
| Exact Sciences Corporation | $17.91 | 2025 | Cologuard Collection Kit |
| Baxter Healthcare | $16.09 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Ultragenyx Pharmaceutical INC. | $16.01 | 2023 | Crysvita |
| Phadia US INC. | $15.80 | 2023 | Immunocap |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.90 | 2019 | |
| Fresenius USA Marketing, INC. | $13.95 | 2019 | |
| Daiichi Sankyo INC. | $13.92 | 2022 | |
| Genentech USA, INC. | $13.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.